...
首页> 外文期刊>The Pediatric infectious disease journal >Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay
【24h】

Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay

机译:乌拉圭一家儿科转诊医院普遍接种7/13价肺炎球菌结合疫苗和b型流感嗜血杆菌结合疫苗后肺炎住院治疗的变化

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In 1994, Uruguay included Haemophilus influenzae b (Hib) conjugated vaccine in a 3 + 1 schedule. In March 2008, 7-valent pneumococcal conjugate vaccines (PCV7) was included in a 2 +1 schedule. In 2010, 13-valent PCV replaced PCV7. Catch-up immunization was offered. The aim of this study was to describe the etiology of community-acquired pneumonia (CAP) in children 0-14 years of age hospitalized at the Hospital Pediatrico-Centro Hospitalario Pereira Rossell between 2003 and 2012. METHODS: Annual hospitalization rates (per 10,000 discharges) for CAP and bacterial-confirmed CAP in children 0-14 years of age was described prior PCV7 vaccination (2003-2007), during the year of implementation of PCV7 (2008) and after the introduction of PCV7 (2009-2012). Data regarding age, strains isolated from pleural fluid and/or blood, vaccination status, pneumococcal and H. influenzae serotypes were obtained from Hospital Pediatrico-Centro Hospitalario Pereira Rossell databases and vaccination records. RESULTS: Hospitalization rates for CAP and pneumococcal CAP between prevaccine years and the last year after introduction of vaccination with PCV (2012) significantly decreased by 78.1% and 92.4%, respectively. Significant reduction for 13-valent PCV vaccine serotypes and significant increase for nonvaccine serotypes was observed. A decrease in Staphylococcus aureus pneumonia was observed. Hospitalization rates for H. influenzae CAP remain stable before and after pneumococcal vaccination. CONCLUSIONS: Three years after PCV7/13 introduction into the routine vaccination schedule, there was a rapid and significant reduction in rates of CAP and P-CAP. An increase of etiology of CAP by other agents was not observed.
机译:背景:1994年,乌拉圭将流感嗜血杆菌b(Hib)结合疫苗列入3 +1时间表。在2008年3月,将2价肺炎球菌结合疫苗(PCV7)列入2 +1时间表。 2010年,13价PCV取代了PCV7。提供了追赶免疫。这项研究的目的是描述2003年至2012年间在Pediatrico-Centro Hospitalario Pereira Rossell医院住院的0-14岁儿童的社区获得性肺炎(CAP)的病因。方法:年住院率(每10,000次出院) )描述了在PCV7接种之前(2003-2007),实施PCV7的当年(2008)和引入PCV7之后(2009-2012)的0-14岁儿童的CAP和细菌确诊的CAP。有关年龄,从胸腔积液和/或血液中分离出的毒株,疫苗接种状况,肺炎球菌和流感嗜血杆菌血清型的数据可从医院儿科中心医院Pereira Rossell数据库和疫苗接种记录中获得。结果:在接种疫苗前和接种PCV疫苗后的最后一年之间(2012年),CAP和肺炎球菌CAP的住院率分别显着降低了78.1%和92.4%。观察到13价PCV疫苗血清型显着减少,非疫苗血清型显着增加。观察到金黄色葡萄球菌肺炎减少。肺炎球菌疫苗接种前后,流感嗜血杆菌CAP的住院率保持稳定。结论:将PCV7 / 13纳入常规疫苗接种计划三年后,CAP和P-CAP的发生率迅速且显着降低。没有观察到其他药物导致的CAP病原学增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号